NCT01625000View on ClinicalTrials.gov

Safety and Efficacy of MP-214 in Patients With Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

October 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

MP-214 3mg

Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.

DRUG

MP-214 6mg

Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.

DRUG

MP-214 9mg

Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.

DRUG

Risperidone 4mg

Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.

DRUG

Placebo

Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.

Trial Locations (3)

Unknown

Sapporo

Seoul

Taipei

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY